Entyvio

Entyvio

vedolizumab

Manufacturer:

Takeda

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Vedolizumab
Indications/Uses
Moderate to severe active ulcerative colitis & Crohn's disease in adult patients who had inadequate response w/, lost response to or were intolerant to either conventional therapy or tumor necrosis factor-α (TNFα) antagonist.
Dosage/Direction for Use
300 mg IV infusion at wk 0, 2 & 6 wk then every 8 wk thereafter, may be increased to every 4 wk.
Contraindications
Special Precautions
Discontinue use if severe infusion-related, anaphylactic or other severe reactions occur or progressive multifocal leukoencephalopathy is confirmed. Not to be administered as IV push or bolus. Not to be initiated in active, severe infections eg, TB, sepsis, cytomegalovirus, listeriosis & opportunistic infections. Controlled chronic or history of recurring severe infection. Increased risk of malignancy. Not recommended in patients previously treated w/ biologic immunosuppressants eg, natalizumab. Concomitant use w/ non-live & live vaccines. May affect ability to drive & use machines. Renal or hepatic impairment. Pregnancy & lactation. Ped patients ≤17 yr.
Adverse Reactions
Nasopharyngitis; headache; arthralgia. URTI, bronchitis, flu, sinusitis; cough, oropharyngeal pain; nausea; rash, pruritus; back pain, pain in extremities; pyrexia, fatigue.
MIMS Class
GIT Regulators, Antiflatulents & Anti-Inflammatories / Immunosuppressants
ATC Classification
L04AG05 - vedolizumab ; Belongs to the class of monoclonal antibodies. Used as immunosuppressants.
Presentation/Packing
Form
Entyvio infusion conc 300 mg
Packing/Price
(single-dose) 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in